Patents Represented by Attorney, Agent or Law Firm Martin Hay
  • Patent number: 5606062
    Abstract: This invention provides novel decahydroisoquinoline compounds which are useful as excitatory amino acid receptor antagonists and in the treatment of neurological disorders. This invention also provides synthetic methods for preparing decahydroisoquinolines, as well as, novel intermediates in the synthesis thereof.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: February 25, 1997
    Assignee: Eli Lilly and Company
    Inventor: Bret Huff
  • Patent number: 5596106
    Abstract: This invention discloses methods of using certain aryl-benzo[b]thiophene and benzo[b]furan compounds to block or inhibit cannabinoid receptors in mammals. It also discloses novel compounds which are antagonists of the cannabinoid receptors and also discloses pharmaceutical formulations which contain the compounds as an active ingredient.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: January 21, 1997
    Assignee: Eli Lilly and Company
    Inventors: George J. Cullinan, Kennan J. Fahey, Gary A. Koppel
  • Patent number: 5591867
    Abstract: This invention provides a process for preparing kainic acid and provides intermediates in the synthesis thereof.
    Type: Grant
    Filed: October 30, 1995
    Date of Patent: January 7, 1997
    Assignee: Eli Lilly and Company
    Inventor: James A. Monn
  • Patent number: 5589501
    Abstract: A pharmaceutical compound of the formula ##STR1## in which m is 0, 1 or 2, n and q are each 0 or 1 to 5, and p is 0 or 1, X is --CO.sub.2 H or tetrazolyl,Y is --CH.dbd.CH--, andZ is(i) phenyl, naphthyl or thienyl, said phenyl, naphthyl and thienyl being optionally substituted,(ii) --CHR.sup.1 R.sup.2 where R.sup.1 and R.sup.2 are each phenyl, naphthyl or thienyl, said phenyl, naphthyl and thienyl being optionally substituted,(iii) .dbd.CR.sup.1 R.sup.2 where R.sup.1 and R.sup.2 are each phenyl, naphthyl or thienyl, said phenyl, naphthyl and thienyl being optionally substituted, or(iv) ##STR2## where r is 0 or 1 to 3 and the phenyl rings are optionally substituted; provided that when Z is phenyl and m is 1, p is 1; and salts and esters thereof.
    Type: Grant
    Filed: November 22, 1994
    Date of Patent: December 31, 1996
    Assignees: Eli Lilly and Company, Universite Louis Pasteur, Lilly, S.A.
    Inventors: Jesus E. Carrera, Almudena R. Esteban, Andr e Mann, Ang ele Schoenfelder, Darryle D. Schoepp, Concepcion P. Tercero, Camille-Georges Wermuth
  • Patent number: 5583221
    Abstract: Compounds having the formula ##STR1## methods for using such compounds to inhibit protein kinase C in animals, including man are useful as inhibitors of protein kinase C. Also disclosed are pharmaceutical compositions including such compounds and compounds having the formula.
    Type: Grant
    Filed: February 23, 1995
    Date of Patent: December 10, 1996
    Assignee: Eli Lilly and Company
    Inventors: Hong Hu, G. Erik Jagdmann, Jr., Jose S. Mendoza
  • Patent number: 5576323
    Abstract: The present invention provides novel compounds that affect excitatory amino acid receptors and are useful in the treatment of neurological disorders. This invention also provides synthetic methods for the preparation of the novel compounds.
    Type: Grant
    Filed: October 13, 1994
    Date of Patent: November 19, 1996
    Assignee: Eli Lilly and Company
    Inventors: Lawrence J. Heinz, William H. W. Lunn, Darryle D. Schoepp
  • Patent number: 5527810
    Abstract: This invention provides novel decahydroisoquinoline compounds which are useful as excitatory amino acid receptor antagonists and in the treatment of neurological disorders. This invention also provides synthetic methods for preparing decahydroisoquinolines.
    Type: Grant
    Filed: June 8, 1994
    Date of Patent: June 18, 1996
    Assignee: Eli Lilly and Company
    Inventor: Paul L. Ornstein
  • Patent number: 5491241
    Abstract: This invention provides novel bicyclic compounds which are useful as excitatory amino acid receptor antagonists and in the treatment of neurological disorders. This invention also provides intermediates useful in the synthesis of excitatory amino acid antagonists.
    Type: Grant
    Filed: October 18, 1993
    Date of Patent: February 13, 1996
    Assignee: Eli Lilly and Company
    Inventor: James A. Monn
  • Patent number: 5470865
    Abstract: The present invention provides an odorless pharmaceutical composition of nizatidine. It also provides a novel form of nizatidine and a process for the preparation of this form.
    Type: Grant
    Filed: August 30, 1994
    Date of Patent: November 28, 1995
    Assignee: Eli Lilly and Company
    Inventors: Mary K. McCauley, Kenneth P. Moder, Jeffrey L. Speakman
  • Patent number: 5461156
    Abstract: This invention provides a process for the stereocontrolled synthesis of cis-bicyclic compounds, including cis-hexahydro-6-isoquinolones, cis-dihydroisochromanones, cis-dihydrothiochromanones, and cisbicyclo[4.4.0]dec-3-ene-2-ones.
    Type: Grant
    Filed: March 31, 1993
    Date of Patent: October 24, 1995
    Assignee: Eli Lilly and Company
    Inventors: Vien V. Khau, Michael J. Martinelli, Barry C. Peterson, Kevin A. Sullivan
  • Patent number: 5446051
    Abstract: The present invention provides novel decahydroisoquinoline derivatives which are useful as excitatory amino acid antagonists. The invention also provides for methods of using these derivatives to treat various neurological disorders.
    Type: Grant
    Filed: May 31, 1994
    Date of Patent: August 29, 1995
    Assignee: Eli Lilly and Company
    Inventor: Paul L. Ornstein
  • Patent number: 5441984
    Abstract: The present invention provides novel urea, thiourea and guanidine derivatives, pharmaceutical formulations thereof and a method of using same to prevent diabetic complications.
    Type: Grant
    Filed: November 14, 1994
    Date of Patent: August 15, 1995
    Assignee: Eli Lilly and Company
    Inventors: William F. Heath, Jr., Jill A. Panetta, John K. Shadle